drugset / Trial / NCT07531108

Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

NCT07531108

Phase 4 Completed 186 enrolled Hawler Medical University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study compared the impacts of empagliflozin-metformin, sitagliptin-metformin, and metformin monotherapy in treatment-naive overweight or obese adults with newly diagnosed type 2 diabetes mellitus in Erbil, Iraq. The study monitored participants for 12 weeks. It determined changes in serum omentin-1, resistin, glycemic markers, and anthropometric measures.

Timeline

Start
2024-11-15
Primary completion
2025-11-27
Completion
2025-11-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule Oral
Comparator Metformin Small molecule Oral
Comparator Sitagliptin Small molecule Oral